Evidence map›Paper›PMID 30590041›Full record

ArticleCell reports2018

Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.

Giusy Tornillo, Catherine Knowlson, Howard Kendrick, Joe Cooke, Hasan Mirza, Iskander Aurrekoetxea-Rodríguez, Maria D M Vivanco, Niamh E Buckley, Anita Grigoriadis, Matthew J Smalley

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cancers · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Giusy TornilloEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK.
Catherine KnowlsonCentre for Cancer Research and Cell Biology, Queens University Belfast, 97 Lisburn Rd, Belfast BT9 7AE, UK.
Howard KendrickEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK.
Joe CookeEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK.
Hasan MirzaSchool of Cancer & Pharmaceutical Sciences, CRUK King's Health Partners Centre, King's College London, Innovation Hub, Comprehensive Cancer Centre at Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
Iskander Aurrekoetxea-RodríguezCenter for Cooperative Research in Biosciences, CIC bioGUNE, 48160 Derio, Spain.
Maria D M VivancoCenter for Cooperative Research in Biosciences, CIC bioGUNE, 48160 Derio, Spain.
Niamh E BuckleySchool of Pharmacy and Centre for Cancer Research and Cell Biology, Queens University Belfast, 97 Lisburn Rd, Belfast BT9 7AE, UK.
Anita GrigoriadisSchool of Cancer & Pharmaceutical Sciences, CRUK King's Health Partners Centre, King's College London, Innovation Hub, Comprehensive Cancer Centre at Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
Matthew J SmalleyEuropean Cancer Stem Cell Research Institute, School of Biosciences, Hadyn Ellis Building, Cardiff University, Cardiff CF24 4HQ, UK. Electronic address: smalleymj@cardiff.ac.uk.
Cardiff University · GBCIC bioGUNE · ESQueen's University Belfast · GBGuy's Hospital · GBKing's College London · GB

Funding

Breast Cancer Now 2012MAYPR076Breast Cancer Now 2012MAYSF122Breast Cancer Now 2013NOVPHD184Cancer Research UK 15938Cancer Research UK A15938
6 · The paper itself

Abstract

The SRC-family kinase LYN is highly expressed in triple-negative/basal-like breast cancer (TNBC) and in the cell of origin of these tumors, c-KIT-positive luminal progenitors. Here, we demonstrate LYN is a downstream effector of c-KIT in normal mammary cells and protective of apoptosis upon genotoxic stress. LYN activity is modulated by PIN1, a prolyl isomerase, and in BRCA1 mutant TNBC PIN1 upregulation activates LYN independently of c-KIT. Furthermore, the full-length LYN splice isoform (as opposed to the Δaa25-45 variant) drives migration and invasion of aggressive TNBC cells, while the ratio of splice variants is informative for breast cancer-specific survival across all breast cancers. Thus, dual mechanisms-uncoupling from upstream signals and splice isoform ratios-drive the activity of LYN in aggressive breast cancers.

Indexed as

AdolescentAdultAnimalsBRCA1 ProteinBreast NeoplasmsCell Line, TumorCell MovementCell ProliferationEpithelial CellsFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansIsoenzymesMiceNeoplasm InvasivenessBRCA1 ProteinBRCA1 protein, humanIsoenzymeslyn protein-tyrosine kinaseNIMA-Interacting Peptidylprolyl IsomerasePIN1 protein, humanProto-Oncogene Proteins c-kitsrc-Family KinasesBRCA1c-KITESRP1LYN kinasePIN1triple-negative/basal-like breast cancer

Identifiers

PMID30590041
PMCPMC6315108
OpenAlexW2902127312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.